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COMMENTS
MARIJUANA AS A SCHEDULE I SUBSTANCE:
POLITICAL PLOY OR ACCEPTED SCIENCE?
Annaliese Smith*
I. INTRODUCTION
In 1970, the United States Congress passed its first com-
prehensive prohibitory drug control statute.1 This statute,
known as the Controlled Substances Act ("CSA"), classifies
substances into five categories based on their medical utility,
abuse potential, and safety of use under medical supervision.
The most restrictive category, known as Schedule I, contains
substances with no currently accepted medical use, high
abuse potential, and a lack of demonstrated safety under
medical supervision.3 Despite disagreement regarding mari-
juana's uses and effects,4 marijuana is a Schedule I sub-
stance.5 This classification is significant because Schedule I
drugs may only be used for research purposes under strict
guidelines.6
Due to the controversial nature of the classification of
marijuana, challenges to its status began soon after enact-
* Articles Editor, Santa Clara Law Review, Volume 40. J.D. candidate,
Santa Clara University School of Law; B.S., University of Michigan.
1. See Comprehensive Drug Abuse Prevention and Control Act of 1970,
Pub. L. No. 91-515, 84 Stat. 1236 (codified as amended in scattered sections of
21 U.S.C.).
2. See Rick J. Strassman, Human Hallucinogenic Drug Research in the
United States: A Present-Day Case History and Review of the Process, 23(1) J.
PSYCHOACTIVE DRUGS 29 (1991).
3. See 21 U.S.C. § 812 (1994).
4. See infra notes 112-13 and accompanying text.
5. See 21 C.F.R. § 1308.11 (1998).
6. See 21 U.S.C. § 823.
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ment of the statute. Numerous criminal cases unsuccessfully
challenged the constitutionality of the CSA.7 The first ad-
ministrative petition challenging the Schedule I status of
marijuana occurred in 1972.' This began a twenty-year
struggle between the Drug Enforcement Administration
("DEA") and private organizations" to reschedule marijuana
to recognize its accepted medical uses."
This comment traces the history of the legal status of
marijuana in the United States"2 and argues for the resched-
uling of marijuana'3 through an objective analysis of the
chemical properties of the substance.'4 To explore how mari-
juana became a Schedule I substance, Part II of this comment
first provides a brief history of marijuana use in America."
To provide the non-scientific reader with the requisite foun-
dation to evaluate the scientific data on marijuana, Part II
then discusses the basic biochemical properties of mari-
juana,'6 as well as a recent report released by the Institute of
Medicine regarding marijuana.' 7 Part II then traces the his-
tory of drug criminalization statutes in the United States to
better understand how the current scheduling scheme came
into existence.'8 Finally, Part II examines past attempts to
challenge the scheduling status of marijuana to show what
approaches failed and the arguments from both sides of the
debate.'9
7. See discussion infra Part II.E.1.
8. A petition may be filed with the Administrator of the Drug Enforcement
Agency to reschedule a controlled substance. See 21 U.S.C. § 811.
9. See National Org. for the Reform of Marijuana Laws v. Ingersoll, 497
F.2d 654 (D.C. Cir. 1974).
10. The National Organization for the Reform of Marijuana Laws, the Alli-
ance for Cannabis Therapeutics, and the Drug Policy Foundation are the prin-
cipal organizations involved in challenging the Schedule I status of marijuana.
See discussion infra Part II.E.2.
11. See discussion infra Part II.E.2.
12. See discussion infra Part II.D.
13. See discussion infra Part V.
14. See discussion infra Part IV.
15. See discussion infra Part II.A.
16. See discussion infra Part II.B. The author in no way intends to imply
that this cursory overview of the data is sufficient for a comprehensive evalua-
tion of the scheduling status of marijuana. The overview of the data is intended
only to highlight available data and an actual petition for rescheduling would
obviously consist of the specifics of many studies.
17. See discussion infra Part II.C.
18. See discussion infra Part II.D.
19. See discussion infra Part II.E.
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Part III of this comment briefly identifies the problems of
the current scheduling status of marijuana.2 ° Part IV ana-
lyzes the medical and scientific data now available on the bio-
chemical, neurological, and medical effects of marijuana.2'
Finally, Part V presents a proposal for a petition to resched-
ule marijuana under the CSA. Specifically, Part V suggests
that marijuana should be a Schedule III substance, although
a transfer into Schedule II is a more feasible goal.22 In the al-
ternative, Part V suggests that the government should con-
sider a unique schedule for marijuana.23
II. BACKGROUND
A. History of Marijuana Use
There is evidence of the human use of the psychoactive
drug, marijuana,24 throughout history. The earliest known
reference to marijuana comes from a Chinese treatise on
pharmacology in 2737 B.C.2 Marijuana use began in the
western world around 1545 A.D. when the Spanish introduced
the plant to Chile.26  By the eighteenth century, Virginians
used the fiber of marijuana to make rope and possibly for rec-
reational purposes as well. 27 Hemp cultivation in the United
States declined, however, with the advent of more profitable
20. See discussion infra Part III.
21. See discussion infra Part IV.
22. See discussion infra Part V.
23. See discussion infra Part V.
24. The hemp plant from which marijuana comes, Cannabis sativa, grows
throughout the world and flourishes in most temperate and tropical regions.
See GERALD F. UELMEN & VICTOR G. HADDOX, DRUG ABUSE AND THE LAW
SOURCEBOOK 2-100 (2d ed. 1998). Cannabis plant products have variously been
called marijuana, hashish, charas, bhang, ganja, and sinsemilla, each varying in
their content of delta-9-tetrahydrocannibinol, the active ingredient in mari-
juana. See ROBERT M. JULIEN, A PRIMER OF DRUG ACTION 330 (1995). The
U.S. Code defines marijuana as "all parts of the plant Cannabis sativa L.,
whether growing or not; the seeds thereof; the resin extracted from any part of
such plant; and every compound, manufacture, salt, derivative, mixture, or
preparation of such plant, its seeds or resin." 21 U.S.C. § 802 (16) (1994).
25. See EDWARD M. BRECHER, LICIT & ILLICIT DRUGS 397 (Consumer Re-
ports eds., 1972).
26. See id. at 403.
27. See JULIEN, supra note 24, at 332. This comment extensively cites this
source due to a lack of extensive research in this field. Dr. Robert M. Julien is
considered an expert in this area and A Primer of Drug Action is a reliable
source of current data. But see generally supra note 16.
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crops such as cotton.28 Recreational use of marijuana existed
throughout the nineteenth and early twentieth centuries.2 9
Only during the 1960s, however, did marijuana as a recrea-
tional drug became popular."°
Americans have historically used marijuana for its me-
dicinal effects. During the 1800s, pharmacologists recom-
mended marijuana for its analgesic and sedative properties to
treat disorders such as dysmenorrhea, migraines, and painful
terminal illnesses.3' However, aspirin and barbiturates be-
came popular in the early 1900s and soon "the hypodermic
syringe made rapid delivery of water-soluble opiates possi-
ble."32  Doctors preferred these opiates to the weaker and
slower-acting cannabis extracts.3 The identification and syn-
thesis of THC in the 1970s made systemic administration of
marijuana possible, reawakening interest in its therapeutic
potential.34
B. The Basic Biochemical Properties of Marijuana and Its
Effects on the Human Body
1. Biochemical Properties
The effects of a drug on the human body depend upon
how much of the drug is ingested, how it is ingested and how
much of the drug is actually absorbed. This involves admini-
stration and absorption into the body; distribution throughout
the body; interaction of the drug with receptors in the body
(resulting in the drug's actions); and, finally, elimination from
the body.35
The major psychoactive ingredient of the marijuana plant
is delta-9-tetrahydrocannabinol ("THC"). 6 Marijuana prod-
28. See BRECHER, supra note 25, at 404.
29. See id. at 409.
30. See id.
31. See Russell Noyes, Jr. et al., The Analgesic Properties of delta-9-
tetrahdrocannabinol and Codeine, 18(1) CLINICAL PHARMACOLOGY AND
THERAPEUTICS 84 (1975).
32. Id.
33. See id.
34. See id.
35. See JULIEN, supra note 24, at 6.
36. See UELMEN & HADDOX, supra note 24, at 2-100.
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ucts vary in THC concentration from one to seven percent;37
most marijuana available in the United States has a THC
content of three to four percent. 3' THC consumption usually
occurs by smoking marijuana. Therefore, the quantity of
THC absorbed varies with the previous smoking experience of
the user, amount of time smoke is held in the lungs, and
amount ingested.
Marijuana products are insoluble in water and improper
for injection." Therefore, inhalation and oral ingestion are
the sole methods of administration available.4' The absorp-
tion of inhaled drugs is rapid and complete, 4' resulting in the
onset of behavioral effects within minutes after smoking, and
reaching peak concentrations in the plasma quickly.43 The ef-
fects seldom last longer than three to four hours, unless the
user smokes more of the drug during this period." If taken
orally, THC absorption is slow and incomplete because this is
a less efficient form of administration. The onset of effects
usually occurs in three to sixty minutes and peak effects oc-
cur two to three hours after ingestion.4 ' THC is three times
more effective when smoked than when taken orally.46
Once absorbed, THC is distributed to various organs of
the body, especially areas with concentrations of fatty mate-
rial. 7 THC also readily crosses the blood-brain barrier 8 into
the brain.4 9  THC eventually converts to an inactive, excre-
table metabolite."° However, the metabolism of THC is slow,
37. See JULIEN, supra note 24, at 330.
38. See M. Perez-Reyes et al., Pharmacological Effects of Daily Marijuana
Smoking in Humans, 40 PHARMACOLOGY, BIOCHEMISTRY, BEHAVIOR 693
(1991).
39. See JULIEN, supra note 24, at 338.
40. See id. at 340.
41. See id. at 338-40.
42. See id. at 338.
43. See Perez-Reyes, supra note 38, at 692.
44. See JULIEN, supra note 24, at 338.
45. See id.
46. See id.
47. See David E. Smith, Review of the American Medical Association Council
on Scientific Affairs Report on Medical Marijuana, 30(2) J. PSYCHOACTIVE
DRUGS 128 (1998).
48. The blood brain barrier is a barrier of specialized cells that not all sub-
stances traverse. Psychoactive substances may cross this barrier and exert
their actions on the brain after crossing. See JULIEN, supra note 24, at 20.
49. See Smith, supra note 47, at 129.
50. See id.
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and therefore low levels of THC persist in the body for several
days or even weeks.5'
2. Effects of Marijuana
a. Internal Effects of THC
THC causes an increase in pulse rate and dilation of
blood vessels in the cornea, but does not affect blood pres-
sure. Significantly, dangerous physical reactions to mari-
juana are almost unknown.53 "No human being is known to
have died of an overdosage."5 4 This distinguishes marijuana
from other controlled substances, which universally have the
potential for lethal effects.
Many studies focus on the effects of marijuana in the
brain that may result in changes in cognition, learning, and
attention." These studies show acute marijuana use impairs
the ability to perform complex functions requiring attention
and mental coordination. However, simple reflex activities
are less affected. In chronic users, data indicate that long-
term marijuana use impairs the ability to efficiently process
information.
Like all psychoactive drugs, side effects of marijuana af-
fect systems of the body other than the brain. Inhaling
marijuana has irritant effects on the lungs, but no studies
show a link between marijuana smoking and lung cancer."
Data varies regarding marijuana's effects on the immune sys-
tem. Evidence indicates that long-term use may cause a de-
gree of immunosuppression.5 Studies show the presence of
cannabinoid receptors in the membranes of spleen cells that,
when activated by THC, reduce the ability of the spleen cells
to function adequately in the immune response.0 Marijuana
51. See id.
52. See JULIEN, supra note 24, at 340-41.
53. See id.
54. See id.
55. See id. at 342.
56. See id.
57. See N. Solowij et al., Effects of Long-Term Cannabis Use on Selective At-
tention: An Event-Related Potential Study, 40 PHARMACOLOGY, BIOCHEMISTRY,
BEHAVIOR 683 (1991).
58. See JULIEN, supra note 24, at 346.
59. See L.E. Hollister, Marijuana and Immunity, 20 J. PSYCHOACTIVE
DRUGS 5 (1988).
60. See Norbert E. Kaminski et al., Identification of a Functionally Relevant
1142 [Vol. 40
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also effects the reproductive systems of men and women, but
all effects appear reversible upon discontinuation of use.61
While tolerance to cannabis occurs,62 physical dependence
on THC does not develop.6" "[C]hronic heavy use of cannabis
does not result in a withdrawal syndrome with severe symp-
tomatology."64 Dependence on the drug is more likely to be
psychological than physical.65
b. Behavioral Effects
Marijuana has sedative, euphoriant, and, when taken in
large doses, hallucinogenic properties.66 At low to moderate
doses, clinical effects of marijuana are similar to alcohol and
anti-anxiety agents.67 THC causes an increase in appetite,
dry mouth, and slight nausea.68 At higher doses, THC may
also produce euphoria, hallucinations, and heightened sensa-
tions, effects similar to a mild LSD experience.6 Even at very
high doses, THC does not produce anesthesia, coma, or
death." It is this fact, above all others, that distinguishes
marijuana from other "drugs of abuse."7
3. Therapeutic Uses for THC
There are several recognized therapeutic uses for THC.
THC exhibits mild analgesic properties, serves as an anti-
Cannabinoid Receptor on Mouse Spleen Cells that is Involved in Cannabinoid-
Mediated Immune Modulation, 42 MOLECULAR PHARMACOLOGY 736 (1992).
61. See A. GOLDSTEIN, ADDICTION: FROM BIOLOGY To DRUG POLICY 175
(1994).
62. See JULIEN, supra note 24, at 349.
63. See M.E. Abood & B.R. Martin, Neurobiology of Marijuana Abuse, 13
TRENDS IN PHARMACEUTICAL SCIENCES 202 (1992). Drug tolerance occurs when
there is "a progessively decreasing responsiveness to a drug," i.e., when a person
needs increasingly larger doses to achieve the same effect. JULIEN, supra note
24, at 33. Physical dependency, however, occurs when the drug is needed to
function normally and absence of the drug results in withdrawal. See id. at 35.
64. JULIEN, supra note 24, at 349.
65. See id.
66. See id. at 330.
67. See id. at 330-31.
68. See id. at 341.
69. See id. at 331. Lysergic acid diethylamide ("LSD") is a semisynthetic
psychedelic drug that evokes perceptual changes, particularly visual hallucina-
tions and perceptual distortions. See id. at 315.
70. See JULIEN, supra note 24, at 331.
71. The phrase "drugs of abuse" is the term usually used in literature and
the media to refer to illicit substances classified as illegal to possess and lead to
psychological and physical dependence (e.g., cocaine and heroine).
11432000]
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epileptic, decreases intraocular pressure in glaucoma pa-
tients, relieves bronchospasm in asthmatics, stimulates the
appetite, and promotes weight gain."2 Currently, two syn-
thetic cannabinoids-dronabinol (otherwise known as "Mari-
nol")7" and nabilone (otherwise known as "Cesamet")-are
available for treatment of nausea and vomiting associated
with chemotherapy in cancer patients.74
C. The Institute of Medicine Report of 1999
The Institute of Medicine ("IOM") was "chartered in 1970
by the National Academy of Sciences to enlist distinguished
members of the appropriate professions in the examination of
policy matters pertaining to the health of the public."75 The
institute's 1999 report, Marijuana and Medicine: Assessing
the Science Base was the result of a request from the White
House Office of National Drug Control Policy ("ONDCP") for
an assessment of the potential health benefits and risks of
marijuana. 6 The study took two years to complete and con-
sisted of the analysis of scientific as well as anecdotal evi-
dence. This multifaceted approach enabled IOM researchers
to examine evidence from unpublished studies.7 ' The IOM
encouraged participation from the public and involved equal
numbers opposed to and in favor of the medical use of mari-
juana.75 After evaluating the evidence, the report concluded
that there are identified medical uses of marijuana but that
the future of drugs consisting of cannabinoids does not in-
volve smoked marijuana."
The study evaluated three areas: the effects of isolated
cannabinoids; the health risks associated with the medical
use of marijuana; and the efficacy of marijuana.' The report
recognized the role of isolated cannabinoids in the brain, sug-
gesting the need for more research on the effects of identifi-
72. See JULIEN, supra note 24, at 344.
73. Dronabinol is THC formulated in sesame oil. See id.
74. See id.
75. INSTITUTE OF MEDICINE, MARIJUANA AND MEDICINE: ASSESSING THE
SCIENCE BASE at 2 (Janet E. Joy et al. eds., National Academy Press 1999).
76. See id. at 7.
77. See id. at 8.
78. See id. at 11.
79. See id. at 8.
80. See id. at 9.
81. See Institute of Medicine, supra note 75, at 2.
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able cannabinoids 2 The study also recognized a potential
therapeutic value of cannabinoid drugs, particularly THC, for
"pain relief, control of nausea and vomiting, and appetite
stimulation." 3 However, because smoking marijuana is a
"crude THC delivery system that also delivers harmful sub-
stances," the report suggested development of reliable and
safe delivery systems. 4
The study acknowledges that marketing a safe delivery
mechanism for cannabinoids is many years away. However,
for many patients with debilitating symptoms, the potential
pain relief far outweighs any potential long-term detrimental
effects. Therefore, smoked marijuana may provide necessary
relief until the development of new THC delivery systems."
The report therefore recommends short-term use of smoked
marijuana under these conditions. 6
While the IOM report has no immediate effect on the
scheduling status of marijuana, it certainly adds impetus to
transfer marijuana from its current Schedule I status. Or-
ganizations fighting to reschedule marijuana rely on the IOM
findings and hope the government no longer denies the scien-
tific conclusions regarding the medicinal value of marijuana."
D. History of Drug Criminalization Statutes
1. Early Development of Drug Laws
The earliest efforts to regulate drugs in the United States
involved taxation.8 In 1915, Congress enacted the Federal
Narcotics Internal Revenue Regulations, 9 commonly called
the Harrison Narcotics Act.9" The bill was not prohibitive but
82. See id.
83. Id. at 3.
84. Id. at 179.
85. See id.
86. See id.
87. See, e.g., Paul Armentano, Federally Commissioned Study Supports
Medical Marijuana, Dismisses Drug's "High Potential For Abuse" (visited Mar.
31, 2000) <httpJ/www.norml.org/medicalliomresponse.shtml>.
88. See ALEXANDER T. SHULGIN, CONTROLLED SUBSTANCES ACT: A
RESOURCE MANUAL OF THE CURRENT STATUS OF THE FEDERAL DRUG LAWS 227
(1988).
89. Harrison Narcotics Act, 26 U.S.C. § 4701 (1915).
90. See SHULGIN, supra note 88, at 227. The Harrison Narcotics Act divided
drugs into four classes. Class A contained highly addictive drugs. Class B con-
tained drugs considered to possess little potential for addiction. The third class,
114520001
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rather a tax measure, drafted to license and tax importers,
manufacturers, sellers and dispensers of opium or cocaine.
The greatest impetus to the outlawing of marijuana oc-
curred during the 1930s. The federal commissioner of nar-
cotics encouraged the states and the Bureau of Narcotics to
vigorously enforce laws against using marijuana. Via the
media, the public believed marijuana was "a potent narcotic
that induced people to commit crimes of violence, led to her-
oin addiction, and was a great social menace."93 Further,
popular culture labeled marijuana as addictive and a cause of
insanity. 4 Amidst these public beliefs, Congress enacted the
Marijuana Tax Act of 1937." This Act required industrial (i.e.
those that used marijuana for industrial purposes only) or
medical users to register and pay a tax of one dollar per
ounce.9" Marijuana used for recreational purposes was taxed
at $100 per ounce.97 From the 1940s through the 1960s, Con-
gress placed various other restrictions on marijuana and
other drugs.
2. The Controlled Substances Act
In 1970, Congress passed the Controlled Substances
Act. The CSA dealt with the problem of drug abuse in the
United States by (1) providing authority to increase efforts for
drug abuse prevention and rehabilitation of users, (2) pro-
viding a more effective means for law enforcement in the ar-
eas of drug abuse prevention and control, and (3) providing a
balanced scheme of criminal penalties for drug offenses.' °
Class X, contained exempt narcotics. The fourth class, Class M, contained "es-
pecially exempt" narcotics. See id.
91. See id.
92. See id. at 229.
93. Id.
94. See id.
95. See Marijuana Tax Act, Pub. L. No. 75-238, ch. 553, 50 Stat. 551 (1937).
96. See Smith, supra note 47, at 128. Although this was a tax act and not
prohibitory in any way, the American Medical Association's Committee on Leg-
islative Activities opposed the passage of the Act, recommending that mari-
juana's status as a medicinal agent be maintained. See id.
97. See id.
98. See SHULGIN, supra note 88, at 229.
99. See Comprehensive Drug Abuse Prevention and Control Act of 1970,
Pub. L. No. 91-515, 84 Stat. 1236 (codified as amended in scattered sections of
21 U.S.C.).
100. See National Org. for the Reform of Marijuana Laws v. Bell, 488 F.
Supp. 123, 126 (D.D.C. 1980).
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The Bureau of Narcotics and Dangerous Drugs, within
the Department of Justice, was the agency appointed to im-
plement the CSA. The primary concerns of the agency were
diversion, distribution, and enforcement.' The CSA dele-
gated responsibility for safe and effective medical use to the
FDA and the role of scientific research to the National Insti-
tute of Drug Abuse ("NIDA").' °2
The CSA placed all medications and drugs of abuse into
five categories based on three factors: (1) medical utility, (2)
abuse potential, and (3) safety of use under medical supervi-
sion. °3 Congress also based the classifications on "certain so-
cial and medical information."0 4 Schedule I is the most re-
strictive category, Schedule V the least restrictive.'0 '
Congress laid out guidelines for each of the five sched-
ules. The CSA requires scientific findings to place a sub-
stance into a specific schedule unless an international treaty,
convention, or protocol in effect on October 27, 1970 dictates
otherwise.' 6 Schedule I drugs must have a high potential for
abuse, no currently accepted medical use in the United
States, and a lack of accepted safety for use under medical
supervision.' 7 Schedule II drugs must have a high potential
for abuse, a currently accepted medical use or a currently ac-
cepted medical use with severe restrictions, and abuse lead-
ing to severe psychological or physical dependence.' 8 Sched-
101. See SHULGIN, supra note 88, at 231.
102. See id.
103. See Strassman, supra note 2, at 29.
104. Bell, 488 F. Supp. at 127 (citing H.R. REP. No. 91-1444 (1970), at 1, re-
printed in 1970 U.S.C.C.A.N. 4566, 4567).
105. See 21 U.S.C. § 812 (1994).
106. See id.
107. See id. Schedule I consists of 42 opiates, 22 opium derivatives (includ-
ing heroin and several structures of codeine and morphine), 17 hallucinogenic
substances (including LSD, marijuana, mescaline, peyote, psilocybin and tetra-
hydrocannabinols), two depressants (including methaqualone), and seven
stimulants. The tetrahydrocannabinols listed on Schedule I are defined as syn-
thetic equivalents of substances contained in the plant or in the resinous ex-
tracts or synthetic substances with similar chemical structure and pharmacol-
ogical activity. See id.
108. See id. Schedule II currently consists of 16 opium and opiate deriva-
tives (including raw, powdered, granulated, fluid and extract of opium, codeine,
and morphine); opium poppy and poppy straw; coca leaves and any derivative or
preparation of (including cocaine); concentrate of poppy straw; 27 opiates (in-
cluding fentanyl and methadone); four stimulants (including amphetamine and
methamphetamine); five depressants (including PCP); and immediate precur-
sors to amphetamine, methamphetamine, and PCP (phencyclidine). See id.
11472000]
SANTA CLARA LAW REVIEW
ule III substances have a potential for abuse less than the
drugs in Schedule I and II, a currently accepted medical use,
and abuse of the drug leading to only moderate or low physi-
cal dependence or high psychological dependence. 9 Schedule
IV drugs have a low potential for abuse relative to the drugs
in Schedule III, a currently accepted medical use in treatment
in the United States, and abuse leading to limited physical
dependence or psychological dependence relative to the drugs
in Schedule III.12 Finally, Schedule V drugs contain low po-
tential for abuse relative to the Schedule IV drugs, a cur-
rently accepted medical use in the United States, and abuse
leading to limited physical dependence or psychological de-
pendence relative to the Schedule IV substances."'
Placing hallucinogens in general, and marijuana in par-
ticular, into Schedule I was controversial. The House Report
recommending marijuana as Schedule I indicates Congress's
uncertainty regarding this classification of marijuana."2 The
report only placed marijuana in Schedule I "at least until the
completion of certain studies now under way" and projected
that the Presidential Commission's recommendations would
"aid in determining the appropriate disposition of this ques-
tion in the future."11  This language indicates that Congress
may have considered that a final placement for marijuana in
another schedule would occur after future research.
The U.S. Attorney General has the authority to add or
transfer a drug between the schedules if the drug meets the
requirements of the target schedule. 4 The Attorney General
also has the authority to remove any drug from the schedules
109. See id. Schedule III consists of four stimulants; ten depressants; nalor-
phine; certain dosages and combinations of narcotic drugs (including codeine,
opium, and morphine); two hallucinogenic substances (dronabinol and nabi-
lone); and anabolic steroids. See id.
110. See id. Schedule IV consists of two narcotic drugs; forty-eight depres-
sants (including alprazolam, chloral hydrate, diazepam, and fenfluramine);
eleven stimulants; and two "other" substances. See id.
111. See 21 U.S.C. § 812. Schedule V consists of one narcotic drug, bupre-
norphine, narcotic drugs such as codeine and opium with non-narcotic medicinal
ingredients at such a proportion to result in medicinal qualities other than
those possessed by the narcotic drug alone, and one stimulant, pyrovalerone.
See id.
112. See National Org. for the Reform of Marijuana Laws v. Ingersoll, 497
F.2d 654, 657 (D.C. Cir. 1974).
113. Id. (quoting from H.R. REP. No. 91-1444 (1970), at 13, reprinted in 1970
U.S.C.C.A.N. 4566, 4579).
114. See 21 U.S.C. § 811.
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if the substance does not meet the requirements for inclusion
in any schedule."5  The Attorney General has historically
delegated this authority to the Administrator of the DEA
("Administrator"). 116
Before initiating proceedings to add, transfer, or delete a
substance from a schedule, the Administrator must request a
scientific and medical evaluation from the Secretary of
Health, Education, and Welfare." 7 Under the CSA, the Ad-
ministrator must also consider the following factors: the
drug's actual or relative potential for abuse; scientific evi-
dence of its pharmacological effect; the state of current scien-
tific knowledge regarding the substance; its history and cur-
rent pattern of abuse; the scope, duration, and significance of
abuse; what, if any, risk there is to public health; the sub-
stance's psychological or physiological dependence liability;
and whether the substance is an immediate precursor of a
substance already controlled under the Act."8
E. Past Attempts to Reschedule Marijuana
The rescheduling of marijuana is not a new idea. Indi-
viduals and organizations have challenged the federal sched-
uling of marijuana on constitutional, practical, and scientific
grounds practically since adoption of the CSA.
1. Criminal Cases Challenging the Schedule I Status of
Marijuana
In the 1973 case of United States v. LaFroscia, a defen-
dant charged with importing and possessing marijuana
brought the first constitutional challenge to the scheduling
status of marijuana on the grounds that "there is no rational
basis for Congress to classify marijuana as a controlled sub-
stance.""' The defendant argued that marijuana should be a
Schedule V, rather than Schedule I, substance. 2 ° The United
115. See id.
116. See Alliance for Cannabis Therapeutics v. DEA, 15 F.3d 1131, 1133
(D.C. Cir. 1994).
117. See 21 U.S.C. § 811(b).
118. See id. 811(c).
119. United States v. LaFroscia, 354 F. Supp. 1338, 1340 (S.D.N.Y. 1973).
120. See id. The defendant had based his unsuccessful scheduling argument
on a report of the Commission on Marijuana and Drug Abuse, a commission es-
tablished by Congress, which proposed a relaxation of the laws regarding
marijuana. See id. at 1341.
114920001
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States District Court for the Southern District of New York
upheld the constitutionality of the CSA on three bases: (1)
Congress has absolute power to prohibit the importation of
narcotics; (2) the illegal importation of marijuana has a harm-
ful effect on the health and general welfare of the American
people;' 21 and (3) the CSA satisfies the obligations of the
United States under its international treaties.'2 2 The court
denied the rescheduling argument as well, claiming that judi-
cial action would be intrusive because the defendant failed to
follow the proper administrative procedures for rescheduling
a controlled substance.'
23
The National Organization for the Reform of Marijuana
Laws ("NORML"), a perennial presence in the rescheduling
battle, began its first constitutional challenge in 1973.2 The
organization filed an action seeking injunctive relief, claiming
constitutional violations of privacy, equal protection, and the
constitutional guarantee against cruel and unusual punish-
ments.'25 Evidentiary hearings,'26 wherein both sides pre-
sented evidence on the effects of marijuana, were not heard
until 1978.127 The court finally issued its decision in 1980, de-
nying the privacy claim on the basis that smoking marijuana
does not qualify as a fundamental right.'28 The court rejected
the equal protection claims on the basis that legislation not
affecting a fundamental right or suspect class need only bear
a rational relationship to a legitimate governmental inter-
est.
29
121. See id. at 1340.
122. See id. at 1341.
123. See id. In 1976, the U.S. District Court in Delaware found that Con-
gress had a rational basis for classifying marijuana as a Schedule I substance.
See United States v. Bergdoll, 412 F. Supp. 1308, 1313 (D. Del. 1976). The court
conceded that opinions vary widely regarding the extent of marijuana restric-
tions but did not explain why the CSA regulations were rational. See id.
124. See National Org. for the Reform of Marijuana Laws v. Bell, 488 F.
Supp. 123, 125 (D.D.C. 1980).
125. See id.
126. The court originally issued a one-year stay while NORML pursued the
administrative avenue to reclassify marijuana. See discussion infra Part II.E.2.
After the stay was vacated, the parties battled over preliminary motions for two
years. See Bell, 488 F. Supp. at 125.
127. See Bell, 488 F. Supp. at 125.
128. See id. at 132.
129. See id. The court cited a report to Congress in which the Department of
Health, Education, and Welfare suggested classification in Schedule I until fur-
ther data could be compiled. See id. at 135 n.32.
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The 1980s brought two more constitutional challenges to
the CSA. In United States v. Fogarty,' the court dismissed
due process and equal protection claims, reasoning that there
was an ongoing debate regarding the therapeutic uses of
marijuana, the standards set out in the CSA are not exclu-
sive, and there remains a problem with marijuana abuse."'
In United States v. Greene,"' the defendant claimed that
charges against him for unlawful distribution of marijuana
violated his due process and free exercise of religion rights. 3'
Despite the testimony of the defendant's expert pharmacolo-
gist,'34 the court rejected the claim in light of the negative
past federal precedent.1
3
'
2. The Petitions to Reschedule
Another route to challenge marijuana's Schedule I status
is by petitioning for rescheduling. Under the CSA, the Ad-
ministrator of the DEA has the authority to reschedule
drugs.'36 In rescheduling a drug, the Administrator must con-
sider '[sicientific evidence of [the drug's] pharmacological ef-
fect, if known,' and '[t]he state of current scientific knowledge
regarding the drug or other substance. Since the early
1970s, several organizations petitioned for the rescheduling of
marijuana.
a. The NORML Petition
NORML filed a rule-making petition in 1972 in the U.S.
Court of Appeals for the D.C. Circuit requesting that mari-
juana either be removed from the CSA entirely or transferred
to Schedule V.'38 The court rejected the petition that same
year, citing United States treaty obligations, but remanded
the issue to the DEA for further consideration, and recom-
mended that the DEA consider separately rescheduling the
130. United States v. Fogarty, 692 F.2d 542 (8th Cir. 1982).
131. See id. at 548.
132. United States v. Greene, 892 F.2d 453 (6th Cir. 1989).
133. See id. at 454.
134. See id. at 455.
135. See id. at 456.
136. See supra text accompanying notes 106-08.
137. Alliance for Cannabis Therapeutics v. DEA, 15 F.3d 1131, 1133 (D.C.
Cir. 1994) (quoting 21 U.S.C. § 811(c)(2), (3) (1994)).
138. See National Org. for the Reform of Marijuana Laws v. Ingersoll, 497
F.2d 654, 655 (D.C. Cir. 1974).
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leaves of the plant.'39 On remand, the administrative law
judge held that cannabis and cannabis resin, as defined in the
treaty, could be rescheduled to Schedule II; that cannabis
leaves could be rescheduled to Schedule V; and that cannabis
seeds and synthetic THC could be removed from the sched-
ules altogether.14' Despite this finding, the Acting DEA Ad-
ministrator claimed an inability to remove marijuana from
Schedule I because it had no currently accepted medical use,
stating that "no matter the weight of the scientific or medical
evidence which petitioners might adduce, the Attorney Gen-
eral could not remove marihuana from Schedule I."'14 In late
1975, NORML filed a petition for review of the Acting Ad-
ministrator's order.1 4 ' This resulted in further argument over
semantics.
The DEA argued that where United States treaty obliga-
tions'43 require a measure of control over a substance, section
811(d) of the CSA4 4 relieves the Administrator of the duty to
refer the petition to the Secretary of Health, Education, and
Welfare.' 4' NORML asserted in response that Section 811(d)
merely authorizes the Administrator to override the Secre-
139. See id. at 656, 660.
140. See National Org. for the Reform of Marijuana Laws v. DEA, 559 F.2d
735, 742 (D.C. Cir. 1977).
141. Id. at 743 (quoting 40 Fed. Reg. 44167 (1975)).
142. See id.
143. The United States ratified the Single Convention on Narcotic Drugs in
1967. See id. at 739. The Single Convention establishes several classifications
of substances, with varying degrees of control attached to each. See id. The
Convention prescribes varying degrees of control to the different parts of the
cannabis plant. The flowering tops of the plant and the cannabis resin are
listed in Schedules I and IV, meaning that production, distribution, and posses-
sion are limited to authorized scientific and medical purposes. Further, a party
state shall prohibit production, manufacture, export, and import of marijuana if
it is the most appropriate means of protecting the public health and welfare.
See id. Because of the treaty's definition of cannabis, the leaves and seeds are
not subject to these controls when separated from the tops of the plant. See id.
144. That section of the CSA provides:
If control is required by United States obligations under in-
ternational treaties, conventions, or protocols in effect on [Oc-
tober 27, 1970], the Attorney General shall issue an order
controlling such drug under the schedule he deems most ap-
propriate to carry out such obligations, without regard to the
findings required by subsection (a) of this section or section
[812 (b) of this title] and without regard to the procedures
prescribed by subsections (a) and (b) of this section.
21 U.S.C. § 811(d)(1) (1994).
145. See DEA, 559 F.2d at 738.
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tary's recommendations to the extent those recommendations
conflict with U.S. treaty commitments.146 Congress resolved
the conflict by requiring the Attorney General to seek advice
from the Secretary of Health, Education, and Welfare and
from the Scientific Advisory Committee.'47 The court deter-
mined that the Attorney General determines the minimum
schedule necessary to meet international obligations, while
the Secretary decides which schedule the substance falls into
according to scientific and medical evidence."'
With that issue settled, the court moved on to the actual
rescheduling arguments. The court found that, "placement in
Schedule I does not appear to flow inevitably from lack of cur-
rently accepted medical use."'49 Rather, the CSA calls for the
balancing of medical usefulness with several other considera-
tions, including potential for abuse and danger of dependence.
Thus, medical use is only one factor.5 ° The court recognized
possible treatment uses of marijuana and recommending fur-
ther study of these possible uses.' Finally, the court re-
manded the case once again for further findings from the Sec-
retary of Health, Education, and Welfare. 2
At this point, NORML incorporated the petitions of indi-
viduals afflicted with various painful diseases and forwarded
it to the Department of Health, Education, and Welfare
("HEW").'53 After two more years of inaction, NORML filed a
complaint alleging that HEW unreasonably delayed action on
the petition.' In response to this complaint, HEW recom-
146. See id. at 739.
147. See id. One of the representatives who sponsored the bill remarked,
"[1]et us also make a definite point of the fact that purely enforcement responsi-
bilities are placed with the Department of Justice while medical and scientific
judgements necessary to drug control are left where they properly should lie
and that is with the Department of Health, Education, and Welfare." See 116
CONG. REC. 33300 (1970).
148. See DEA, 559 F.2d at 747.
149. Id. at 748. Both parties agreed that classification of cannabis and can-
nabis resin under Schedule II still satisfied United States treaty obligations.
See id. at 751. As for seeds capable of germination, the court upheld the acting
Administrator's decision to keep them under Schedule V at the very least. See
id. at 756.
150. See id. In fact, the court cited several Schedule II substances with no
currently accepted medical use, including poppy straw. See id.
151. See id. at 749.
152. See id. at 757.
153. See 1 MARIJUANA, MEDICINE & THE LAW at vi (R.C. Randall ed., 1988).
154. See 1 id.
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mended to the DEA that marijuana remain in Schedule V
Only ten days later, the DEA officially denied NORML's peti-
tion to reschedule.' NORML responded by filing its third
request for review with the U.S. Court of Appeals."7 The U.S.
Court of Appeals responded by ordering the DEA to review
the petition in its entirety, Health & Human Services
("HHS") to make scientific and medical findings on all sub-
stances at issue, and for both government agencies to file
quarterly progress reports with the court.'
In the mid-1980s it appeared that action would finally be
taken as a result of this arduous process. In 1985, the FDA
approved THC in the form of dronabinol for marketing."9 In
1986, the DEA rescheduled synthetic THC to Schedule 11.16 °
The DEA finally called for public hearings on marijuana's
proper classification, as ordered by the Court of Appeals
seven years earlier.16 ' After two years of these hearings, the
administrative law judge ruled that marijuana should be
transferred from Schedule I to Schedule II, based on evidence
that a respectable minority of physicians accept the medical
uses of marijuana. '62  NORML had finally succeeded-until
the Administrator rejected this recommendation, requiring a
greater showing to prove currently accepted medical use be-
fore approving such a transfer.'
63
The Administrator based his rejection of a currently ac-
cepted medical use on an eight-factor test, under which a
drug has a currently accepted medical use if the following fac-
tors can be shown:
(1) Scientifically determined and accepted knowledge of
its chemistry; (2) The toxicology and pharmacology of the
substance in animals; (3) Establishment of its effective-
ness in humans through scientifically designed clinical
trials; (4) General availability of the substance and infor-
mation regarding the substance and its use; (5) Recogni-
155. See 1 id. at vii.
156. See 1 id.
157. See 1 id.
158. See 1 id.
159. See 1 MARIJUANA, MEDICINE & THE LAW, supra note 153, at vii.
160. See 1 id. at viii.
161. See 1 id.
162. See 2 id. at 445.
163. See Alliance for Cannabis Therapeutics v. DEA, 930 F.2d 936, 938 (D.C.
Cir. 1991).
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tion of its clinical use in generally accepted pharmacopeia,
medical references, journals or textbooks; (6) Specific indi-
cations for the treatment of recognized disorders; (7) Rec-
ognition of the use of the substance by organizations or as-
sociations of physicians; and
(8) Recognition and use of the substance by a substantial
segment of the medical practitioners in the United
States.16
The Administrator determined that the chemistry and phar-
macology of marijuana were not established, its effectiveness
in humans was not sufficiently documented in clinical trials,
and it was not generally accepted as medicine.'65
In the 1990s, the Alliance for Cannabis Therapeutics
("ACT") joined NORML in the struggle to reschedule mari-
juana. '66 The groups challenged this most recent rejection by
the DEA by alleging that the Administrator unreasonably
rejected the petition, improperly basing his determination on
the absence of demonstrated scientific evidence, and that the
drug is actually medically useful and safe.'67 Petitioners also
claimed that factors (4), (5), and (8)168 are impossible to
meet.'69 The very nature of the Schedule I classification pre-
vents drugs currently in Schedule I from satisfying these cri-
teria.7 ° Agreeing with the petitioners, the court again re-
manded the petition to the DEA, this time for an explanation
of how these three factors affected the Administrator's deci-
sion. 7' The new Administrator approved his predecessor's de-
termination, concluding that two of the three criteria had not
been relied upon, and the third was explained.'72
ACT, the Drug Policy Foundation ("DPF"), and NORML
appealed this last order of the Administrator.'73 The D.C. Cir-
cuit again upheld the Administrator's rejection, but stated a
164. Id. (citing Schedules of Controlled Substances, 53 Fed. Reg. 5156 (1988)
(codified at 21 C.F.R. pt. 1308)).
165. See id.
166. See id.
167. See id. at 939.
168. See supra text accompanying note 164.
169. See Alliance for Cannabis Therapeutics, 930 F.2d at 940.
170. See id.
171. See id.
172. See Alliance for Cannabis Therapeutics v. DEA, 15 F.3d 1131, 1134
(D.C. Cir. 1994).
173. See id. at 1133.
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new, five-part test 4 to determine currently accepted medical
use.175  This 1994 rejection was the last chapter of the
NORML petition. At this point, the petition, first filed in
1972, has not brought about a change in the scheduling
status of marijuana. However, the many decisions have re-
sulted in greater precision in the statutory guidelines, and a
running sentiment of the court that marijuana has medicinal
value.
b. The Gettman Petition for Repeal of Marijuana
Prohibition (1995)
In July of 1995, Jon Gettman, former NORML national
director and publisher of High Times magazine, filed an ad-
ministrative petition with the DEA claiming that marijuana
lacks the requirements necessary for Schedule I or II status."6
Unlike the past petition challenging the scheduling status on
the grounds of an accepted medical use, the Gettman petition
challenged the status of THC-containing compounds (Sched-
ule I), dronabinol (Schedule II) and nabilone (Schedule II) on
the basis that they do not have sufficient abuse potential. 7
Under the CSA, this petition requires a scientific and medical
evaluation by HHS.7 8 In 1998, the DEA requested the HHS
to conduct a "scientific and medical evaluation of the avail-
able data and provide a scheduling recommendation" for
marijuana and other cannabinoids.' 9 HHS has yet to give its
recommendation.
Since the release of the report by the Institute of Medi-
cine, 8° the petitioners and other advocates hope the HHS
174. Factors to determine whether a drug is in currently accepted medical
use are: (1) the drug's chemistry must be known and reproducible; (2) there
must be adequate safety studies; (3) there must be adequate and well-controlled
studies proving efficacy; (4) the drug must be accepted by qualified experts; and
(5) the scientific evidence must be widely available. See id. at 1135.
175. See id.
176. See Paul Armentano, IOM Findings Challenge Legal Justification for
Marijuana Prohibition (visited Apr. 14, 1999) <http://www.norml.org/medical/
iomresponse.shtml>.
177. See Jon Gettman, Petition for Repeal of a Rule (visited Jan. 19, 1999)
<http://www.norml.org/legal/exa.shtml>. Note, as of July 1999, dronabinol and
nabilone have been placed in Schedule III. See generally supra note 109.
178. See Jon Gettman, Petition to the DEA to Reschedule Marijuana (visited
Mar. 31, 2000) <http://www.norml.org/legal/petition.shtml>.
179. See Armentano, supra note 176.
180. See supra Part II.C.
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study currently underway leads to a grant of the petition to
reschedule."' According to the advocates at NORML:
The burden of proof for maintaining the legal justification
for marijuana prohibition has now shifted to the federal
government and the international prohibitionist commu-
nity. Unless they can produce evidence that finds the [In-
stitute of Medicine]'s conclusions incorrect, they are le-
gally required to end marijuana prohibition by removing
marijuana from Schedule I status. 18 2
III. IDENTIFICATION OF THE PROBLEM
This year marks the thirtieth anniversary of the CSA.
For the statute's entire existence, organizations and indi-
viduals have disagreed upon the scheduling status of one
drug in particular: marijuana. The main issue that challeng-
ers face is how to finally accomplish a successful petition for
rescheduling. This comment attempts to identify a feasible
approach to petitioning by taking an objective approach to the
evidence and attacking the current status of marijuana on
every prong of the test.
IV. ANALYSIS
Determining which schedule is appropriate for marijuana
under the CSA requires evaluation of the factors used to
categorize substances. Originally, courts classified sub-
stances based on (1) their accepted medical use, (2) abuse po-
tential, and (3) safety of use under medical supervision. 8'
The DEA later identified five factors to determine whether a
drug is currently medically accepted: (a) the drug's chemistry
must be known and reproducible; (b) there must be adequate
safety studies; (c) there must be adequate and well-controlled
studies proving efficacy; (d) the drug must be accepted by
qualified experts; and (e) the scientific evidence must be
widely available.' The current medical evidence on mari-
juana requires evaluation using these guidelines to determine
the proper classification of marijuana.
181. See Armentano, supra note 176.
182. Id.
183. See supra text accompanying note 103.
184. See supra note 174.
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A. The Medical Utility of Marijuana
Numerous studies show that marijuana is effective in re-
ducing nausea and vomiting,'85 lowering intraocular pressure
associated with glaucoma, 18 6 and decreasing muscle spasm
and spacticity' 87 Numerous AIDS and cancer patients smoke
marijuana to combat nausea and vomiting. 8' In fact, one
survey revealed that forty-four percent of oncologists recom-
mended marijuana to their cancer patients.'89
Foes of the medical marijuana movement identify Mari-
nol, a prescription drug containing THC, as an adequate al-
ternative to smoked marijuana. Although marketed in the
United States as an anti-emetic, 9 ° this synthetic THC has se-
rious cost-related and pharmacological drawbacks. A patient
taking a normal prescription of three five-milligram tablets of
Marinol per day spends over $5,000 in one year. 9' The phar-
macological drawbacks of Marinol relate to its intake in oral
form.'92 Oral ingestion of THC means a slower entrance into
the bloodstream, yielding lower concentrations per dose. '
Oral THC stays in the body longer at effective concentrations
and more THC metabolizes to an active compound. There-
fore, oral THC more frequently results in unpleasant psy-
choactive effects.'94 Furthermore, for patients suffering from
nausea, the act of swallowing the capsules may provoke vom-
iting.9 Therefore, while Marinol may be an effective drug for
some patients, economic and pharmaceutical drawbacks
185. See A.E. Chang et al., Delta-9-Tetrahydrocannibinol as an Antiemetic in
Cancer Patients Receiving High-Dose Methotrexate: A Prospective Randomized
Evaluation, 91 ANNALS OF INTERNAL MED. 819 (1979).
186. See R.S. Hepler & I.R. Frank, Marijuana Smoking and Intraocular
Pressure, 217 JAMA 1392 (1971).
187. See D.J. Petro, Marijuana as a Therapeutic Agent for Muscle Spasm or
Spasticity, 21 PSYCHOSOMATICS 81 (1980).
188. See Lynn Zimmer & John P. Morgan, Exposing Marijuana Myths: A Re-
view of Scientific Evidence (visited Oct. 10, 1995) <http://www.pdxnorml.org/
Exposing-index_1095.html>.
189. See R. Doblin & M.A.R. Kleiman, Marijuana as an Anti-Emetic Medi-
cine: A Survey of Oncologists' Attitudes and Experiences, 19 J. OF CLINICAL
ONCOLOGY 1275, 1285 (1991).
190. An anti-emetic is a substance that decreases vomiting. See Zimmer &
Morgan, supra note 188.
191. See id.
192. See id.
193. See id.
194. See id.
195. See id.
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greatly limit its utility. By permitting the therapeutic use of
Marinol, the government has implicitly conceded that THC is
a medically effective drug. Allowing patients to smoke the
natural plant allows them to ingest the medically useful sub-
stance, THC, in a more efficient, and in some cases, more
medically practical form.196 The following analysis of the
DEA's five factors in turn indicates the medical utility of
marijuana.
1. Known and Reproducible Drug Chemistry
THC is the principal active component in marijuana, but
there may also be other active compounds in cannabis that
produce psychoactive effects.'97 In fact, at least sixty other
cannabinoids have been isolated and identified.9 Scientists
can identify and synthesize the chemical characteristics and
structure of THC.'99 The pharmacokinetics, receptor path-
ways, and receptor sites in the brain have been identified. °0
These findings produce a complete picture of the biochemistry
and activity in the brain of marijuana, meaning that the
chemistry of the drug is known and reproducible.
2. Adequate Safety Studies
Numerous studies exist that examine the effects of THC
on the brain. Early studies in monkeys indicated that THC
caused structural changes in the hippocampus, a brain region
important in learning and memory.20 ' However, the monkeys
in those studies ingested massive doses of THC, up to 200
times the psychoactive dose in humans.2 2 Later studies ad-
ministering 100 times the human dose failed to reveal any
damage.03 Studies testing cognitive functions in humans in-
196. However, some argue that there may be other psychoactive compounds
in the plant that have not yet been isolated. See National Institutes of Health,
Workshop on the Medical Utility of Marijuana (visited Jan. 19, 1999)
<http://www.health.org/pubs/qdocs/marij/medicalmarijuana.htm>. If this is so,
the efficacy of the natural form may be greater due not only to the form of inges-
tion, but also to these other compounds.
197. See National Institutes of Health, supra note 196.
198. See Smith, supra note 47 at 128.
199. See id. at 128-29.
200. See id at 129.
201. See Zimmer & Morgan, supra note 188.
202. See id.
203. See id.; see also W. Slikker et al., Behavioral, Neurochemical, and Neu-
rohistological Effects of Chronic Marijuana Smoke Exposure in the Nonhuman
11592000]
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dicate that marijuana does not affect the retrieval of informa-
tion learned previously."4 However, evidence suggests that
marijuana in high doses may interfere with the ability to
transfer new information into long-term memory."' These re-
sults indicate that adequate safety studies exist.
3. Adequate and Well-Controlled Studies Proving
Efficacy
a. Hurdles to Scientific Studies of the Efficacy of
Marijuana
Several challenges exist in conducting a well-controlled
study of marijuana and its therapeutic effects. First, many
previous studies reflect biased results. The sponsors were of-
ten either the federal government or private organizations
whose exclusive purpose was to either challenge or support
the current legal status of marijuana. Second, there are diffi-
culties related to marijuana as an inhalant including vari-
ability of dose, respiratory effects of smoking, and exposure to
other chemicals present in the Cannabis plant."6
Another issue contributing to difficulties in researching
marijuana is its Schedule I status.0 7 Researchers are "uni-
formly pessimistic with regard to human studies ever pro-
ceeding with Schedule I compounds." 8 In addition, private
researchers cannot grow marijuana for research.0 9 The only
legal producer of marijuana in the United States is the Uni-
versity of Mississippi, under an exclusive contract with the
National Institute of Drug Abuse ("NIDA").210 The Compas-
Primate, in MARIJUANA/CANNABINOIDS NEUROBIOLOGY AND
NEUROPHYSIOLOGY 219-74 (L. Murphy & A. Bartke eds., 1992) (discussing
study where rhesus monkeys were exposed to inhalation of equivalent of four or
five marijuana cigarettes per day for one year and no change in brain structure
resulted).
204. See Zimmer & Morgan, supra note 188.
205. See id.
206. See U.S. Department of Health & Human Services, Investigating Possi-
ble Medical Uses of Marijuana (last modified Oct. 8, 1997)
<http://www.waisgate.hhs.gov/cgi-bin/waisgate>.
207. See 21 U.S.C. § 823 (1994).
208. Strassman, supra note 2, at 30.
209. See Alice Mead, Proposition 215: A Dilemma, 30(2) J. OF PSYCHOACTIVE
DRUGS 149, 150 (1998).
210. See id.
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sionate Investigative New Drug ("IND") Program,21' to which
the University of Mississippi supplies marijuana, has the po-
tential to perform a long-term, controlled study. Yet, even
this program has not evaluated the effectiveness of mari-
juana.212 Researchers must obtain approval for the marijuana
directly from the NIDA.212 Therefore, even an FDA-approved
researcher may still be unable to gain approval from NIDA to
conduct research.214
Research with animals is less difficult. However, the
DEA requires storage and disposal facilities, as well as assur-
ance that handlers of the substance do not have a criminal re-
cord."' Despite these obstacles, several studies show the effi-
cacy of marijuana in regards to analgesic effects, treatment of
AIDS wasting syndrome, chemotherapy-induced nausea and
vomiting, and glaucoma.
b. Analgesic Effects
In a 1975 study at the Departments of Psychiatry and
Medicine at the University of Iowa College of Medicine, scien-
tists demonstrated the analgesic effects of THC in patients
with cancer pain. 6 The study compared the pain reduction
effects of codeine and THC, concluding that the analgesic ef-
fect of THC developed gradually and was prolonged as com-
pared to codeine.2 7 The study found negative side effects in
some patients,"' but these side effects were found at dosages
(ten to twenty milligrams) far greater than an average
smoker consumes (the amount of THC absorbed from smok-
ing one marijuana cigarette is four-tenths to ten milli-
211. The IND program was set up in the mid-1970s to provide select patients
with marijuana for therapeutic use. See Abbie Crites-Leoni, Medicinal Use of
Marijuana: Is the Debate a Smoke Screen for Movement Toward Legalization?,
19 J. LEGAL MED. 273, 277 (1998).
212. See id. at 278. Although the program was discontinued, eight patients
were allowed to continue their use through the University of Mississippi in Ox-
ford. See id. Physicians' reports are only used to determine whether or not the
patients should continue to use marijuana, not for evaluative data. See id.;
ROBERT C. RANDALL & ALICE M. O'LEARY, MARIJUANA RX: THE PATIENTS'
FIGHT FOR MEDICINAL POT (1998) (discussing one man's personal history of his
involvement in the program).
213. See Crites-Leoni, supra note 211, at 278.
214. See id.
215. See Strassman, supra note 2, at 31.
216. See Noyes, Jr. et al., supra note 31, at 87.
217. See id. at 86.
218. See id.
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grams 19).
c. Treatment of AIDS Wasting Syndrome
Symptoms of AIDS wasting syndrome include an invol-
untary weight loss of at least ten percent with chronic diar-
rhea, weakness, or fever for thirty days or more, in the ab-
sence of other illnesses contributing to the weight loss. 20 The
severity of the syndrome is pronounced because weight loss is
an independent predictor of short-term survival in AIDS pa-
tients.221' Although there is a lack of published data on mari-
juana usage in AIDS patients with wasting syndrome, data
from placebo-controlled, single-dose studies, and chronic
dosing in normal subjects indicates that smoked marijuana
stimulates appetite and increases caloric intake.222
d. Treatment of Chemotherapy-Induced Nausea and
Vomiting
THC reduces the number of retching and vomiting epi-
sodes, the degree and duration of nausea, and the volume of
emesis in cancer patients undergoing chemotherapy. 22 Reli-
able studies indicate that smoked marijuana yielded higher
plasma concentrations of THC than orally ingested THC.
Further, smoked marijuana was more effective in the relief of
symptoms in patients who previously smoked marijuana.224
e. Treatment of Glaucoma
Marijuana has been proven to exert ocular effects such as
decreased intraocular pressure, pupil constriction, and con-junctival hyperemia.2 5 Although useful in the treatment of
glaucoma, its short duration of action is a significant draw-
back, especially considering that standard treatments are
quite effective. 226 However, two promising, yet unsubstanti-
ated, reports that nonpsychotropic cannabinoids present in
marijuana exert neuroprotective effects that may be impor-
219. See JULIEN, supra note 24, at 338.
220. See Smith, supra note 47, at 129-30.
221. See id. at 130.
222. See id.
223. See id. at 131.
224. See id.
225. See id. at 132.
226. See Smith, supra note 47, at 133.
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tant in delaying retinal cell death call for further study of the
effects of marijuana on glaucoma patients.227
Despite the significant hurdles to reliable scientific
studies of marijuana, there is a wealth of adequate and well-
controlled studies demonstrating its efficacy. Mounting evi-
dence proves its analgesic effects as well as its use in treat-
ment of AIDS wasting syndrome, nausea and vomiting, and
glaucoma.
4. Drug Accepted by Qualified Experts
The fourth factor the DEA identified as relevant to deter-
mine whether a drug is currently medically accepted is the
drug's acceptance by qualified experts.
In presenting the pros and cons of marijuana use in
treatment of a variety of illnesses and disease symptoms,
the committee [American Medical Association Council on
Scientific Affairs] makes clear that, as is the case with
morphine and a variety of other psychoactive substances
that are currently used in the practice of medicine, mari-
juana is both a dangerous street drug and a potentially
useful medication.228
The AMA showed its support for the open discussion of
marijuana as an effective therapeutic agent with patients,
stating that the principles of "free disclosure apply even if the
effectiveness of potential treatment or modality is not yet
fully proven."229
As the debate to legalize marijuana for medicinal pur-
poses heats up, an increasing number of physicians and bio-
medical experts criticize the federal classification of mari-
juana. A commentary in the Journal of the American Medical
Association stated: "It is time for physicians to acknowledge
more openly that the present classification is scientifically,
legally and morally wrong."23 The editor-in-chief of the New
England Journal of Medicine expressed his belief that the
227. See id.
228. David E. Smith et al., Editor's Introduction, 30(2) J. PSYCHOACTIVE
DRUGS 124 (1998).
229. David E. Smith, Review of the American Association Council on Scien-
tific Affairs Report on Medical Marijuana, 30(2) J. PSYCHOACTIVE DRUGS 128
(1998).
230. L. Grinspoon & J. Bakalar, Marihuana as Medicine: A Plea For Recon-
sideration (Commentary), 273(23) JAMA 1876 (1995).
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current federal prohibition of marijuana is "misguided, heavy-
handed, and inhumane."
23
'
When the primary professional organization of American
physicians and many individual doctors publicly state that
marijuana has characteristics of a drug that should not be re-
stricted to Schedule I status, it is safe to say that it is ac-
cepted by qualified experts.
5. Scientific Evidence Widely Available
The final factor of the DEA test for medical acceptance of
marijuana, the availability of scientific evidence, clearly fa-
vors finding marijuana medically accepted. "The issue of
whether marijuana has medicinal benefits no longer seems to
be in question. Hundreds of scientific studies and thousands
of testimonials from patients have established marijuana's ef-
fectiveness." '232 The only limit on the availability of scientific
evidence relates to the need for more research concerning the
therapeutic uses of marijuana.2"3
An objective evaluation of the DEA's five factors indicates
the medical utility of marijuana. The greatest drawback is
the limited research. However, the majority of the existing
research, which is certainly not minimal, proves the safe, re-
liable, medical use of marijuana.
B. Abuse Potential
Merriam Webster's Collegiate Dictionary defines abuse
as "an improper or excessive use or treatment," for example,
the misuse of a drug.2"4 Although this is an ill-defined term, a
drug's tolerance and addictive capacity define its potential for
abuse. Three factors usually determine drug dependence: (1)
preoccupation with the acquisition of the drug; (2) compulsive
use of the drug; and (3) relapse to, or recurrent use of, the
drug.23' These factors are not usually found with marijuana
use alone, but are more common with polydrug dependence.2 6
231. Jerome Kassirer, Editorial: Federal Foolishness and Marijuana, 336
(Jan.) NEw ENGLAND J. MED. 366 (1997).
232. Harvey W. Feldman & Jerry Mandel, Providing Medical Marijuana: The
Importance of Cannabis Clubs, 30(2) J. PSYCHOACTIVE DRUGS 179 (1998).
233. See discussion supra Part IV.A.3.a.
234. MERRIAM WESBTER'S COLLEGIATE DICTIONARY 5 (10th ed. 1993).
235. See JULIEN, supra note 24, at 350.
236. See id.
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Humans develop a tolerance to marijuana,237 including a
tolerance to the effects of marijuana.238 Studies from the
1980s and the early 1990s indicated a physical dependence
upon marijuana and a resulting withdrawal syndrome."'
However, studies since the 1990s indicate otherwise. 20 Any
physical dependence that may occur results in only a mild
withdrawal syndrome consisting of irritability, restlessness,
nervousness, decreased appetite, weight loss, insomnia, re-
bound increase in REM sleep, tremor chills, and increased
body temperature. If this withdrawal syndrome occurs, it
lasts only four to five days.241 Such a mild withdrawal syn-
drome indicates limited possibility for physical addiction.
There may also be limited potential for psychological de-
pendence on marijuana. Studies show that marijuana acti-
vates the brain's central reward systems,242 which usually in-
dicates and characterizes drugs of compulsive abuse and
psychological dependence." 3 However, an almost universal
predictor of psychological dependence is whether an animal
will self-administer the drug when given free access, which
does not occur with products containing THC.244 With limited
potential for physical and psychological dependence, resched-
uling marijuana appears appropriate.
C. Safety Under Medical Supervision
Because of the unlikelihood of negative physical reactions
to marijuana, there is a high safety index when taken under
medical supervision.245 After the passage of Proposition 215
in California,246 the California Society of Addiction Medicine
237. Physical tolerance has been shown by cannabinoid receptor down-
regulation. See F. Rodrigues de Fonseca, Down-regulation of Rat Brain Canna-
binoid Binding Sites After Chronic delta-9-Tetrahydrocannibinol, 47
PHARMACOLOGY, BIOCHEMISTRY, BEHAVIOR 33-40 (1994).
238. See JULIEN, supra note 24, at 349.
239. See Timmen L. Cermak, Addiction Medicine Perspective on the Medicali-
zation of Marijuana, 30(2) J. PSYCHOACTIVE DRUGS 155, 159 (1998) (discussing
studies from this period).
240. See supra notes 62-65 and accompanying text.
241. See JULIEN, supra note 24, at 349.
242. See E.L. Gardner & J.H. Lowinson, Marijuana's Interaction with Brain
Reward Systems: Update 1991, 40 PHARMACOLOGY, BIOCHEMISTRY, BEHAVIOR
571 (1991).
243. See JULIEN, supra note 24, at 349.
244. See Abood & Martin, supra note 63, at 202.
245. See generally supra notes 66-71 and accompanying text.
246. See CAL. HEALTH & SAFETY CODE § 11362.5 (West Supp. 1998). In
116520001
SANTA CLARA LAW REVIEW
("CSAM") set standards for prescribing marijuana for medici-
nal uses.24' These standards include the necessary informa-
tion a physician must share with a patient receiving a pre-
scription for marijuana.248 The CSAM believes that there is a
limited abuse potential of marijuana, but states that these
"known hazards of marijuana simply require [guidelines] to
minimize potential negative effects on individuals for whom
medical use is justified and to minimize legitimate public
health risks."2 '9 These state measures have actually put into
practice marijuana's safety under medical supervision.
The scientific data objectively shows that marijuana has
currently accepted medical uses, that its potential for abuse
does not place it in the category of a Schedule I substance,
and that there is a great likelihood of safety under medical
supervision.
V. PROPOSAL
The current placement of marijuana in Schedule I sug-
gests it has a high potential for abuse, no currently accepted
medical use in the United States, and a lack of safety for use
under medical supervision.5 ° The review of currently avail-
able medical evidence in Part IV of this comment indicates
that this classification is inappropriate.25'
A petition for the rescheduling of marijuana should in-
clude the current medical and scientific data, while avoiding
the mistakes made in past efforts to reschedule.25 ' For exam-
ple, challenging the constitutionality of the Controlled Sub-
stances Act has failed time and again. '53 The petition to re-
schedule filed by NORML in the early 1970s and pursued
until 1994 challenged only the "currently accepted medical
use" prong of the DEA test.54 A current petition should use
1996, 55% of the California voters approved an initiative to legalize marijuana
for medical purposes. The statute allows marijuana use if "recommended by a
physician who has determined the person's health would benefit." Cermak, su-
pra note 239, at 155. Of course, California's initiative, and similar provisions in
other states as well, do not circumscribe the federal CSA.
247. See Cermak, supra note 239, at 157.
248. See id. at 158.
249. Id. at 160.
250. See 21 U.S.C. § 812(b)(1) (1994).
251. See supra Part IV.
252. See supra Part II.E.
253. See supra Part II.E.1.
254. See supra Part II.E.2.
1166 [Vol. 40
MARIJUANA AS SCHEDULE I
scientific data to prove that marijuana (1) has accepted medi-
cal uses, (2) has low abuse potential, and (3) is safe to use un-
der medical supervision. Specifically, the petition should call
for marijuana to be rescheduled to Schedule II at the very
least, but more accurately to Schedule III.
The first factor to be considered is the medical utility of
marijuana, taking into account the five factors that the DEA
identified as pertinent.255 Marijuana has a known and repro-
ducible drug chemistry. 56 Under the "adequate safety stud-
ies" prong, there are no known dangerous physical reactions
to marijuana25 7 and studies indicate no long-term damage in
the brain. Controlled studies demonstrate the efficacy of
marijuana (the third prong) in its analgesic effects, treatment
of AIDS wasting syndrome, treatment of chemotherapy-
induced nausea and vomiting, and treatment of glaucoma.259
In denying a therapeutic drug, the government prevents pa-
tients from receiving medication that may aid their treat-
ment, relieve their pain, or, for some patients, be the only ef-
fective treatment.
Numerous qualified experts indicate that marijuana is
accepted as a medically useful drug. 6° There is a great deal of
scientific research regarding the therapeutic role of mari-
211juana.
Finally, the last two elements of the three-prong test to
reschedule are met. Studies indicate that marijuana has a
limited potential for psychological and physical dependence,
but that humans develop a tolerance to the drug. 62 There is
only a moderate abuse potential for marijuana, especially
when compared with other Schedule I drugs well-known for
their abuse potential.263 Marijuana can also be administered
safely under medical supervision.64
These studies preliminarily indicate that the proper clas-
255. See supra note 174.
256. See supra Part IV.A.1.
257. See supra notes 66-71 and accompanying text.
258. See supra text accompanying notes 201-05.
259. See discussion supra Part IV.A.3.b-e.
260. See discussion supra Part IV.A.4.
261. See discussion supra Part IV.A.5.
262. See discussion supra Part IV.B.
263. See supra note 107.
264. See discussion supra Part IV.C.
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sification of marijuana is under Schedule III.265 However,
without more extensive studies, the lack of conclusiveness of
the results may prevent Schedule III status. In such a case,
classification as Schedule II until further studies are com-
pleted is appropriate. The most compelling argument in favor
of Schedule II status is the almost conclusive evidence that
there is no high potential for abuse of marijuana.
Another important factor to consider regarding resched-
uling is that moving marijuana to Schedule II or Schedule III
greatly increases access to the drug for research. Greater ac-
cess allows for quicker drug development with cannabinoids.
Since marijuana is only useful as an inhalant for some ill-
nesses (such as AIDS wasting syndrome), studies qualifying
its efficacy because of the drawbacks of smoking require a
second look. Products that vaporize marijuana plants so as to
minimize the effects of smoking are being developed and
used.266
An alternative to rescheduling marijuana under Sched-
ules II or III is to classify marijuana in its own schedule. Be-
cause it is relatively easy to grow and harvest, individuals
can easily produce their own marijuana. Instead of spending
time and money prosecuting such individuals, especially
those growing marijuana for personal medical use, the gov-
ernment should create a system of regulation permitting cer-
tain growth of the drug. Marijuana's unique properties, par-
ticularly the impossibility of overdosing, may make a new
classification most appropriate. More research must be con-
ducted on isolated cannabinoids and differing concentrations
in various strains of the plant before implementing a schedule
that permits individual growers to harvest the plant.
VI. CONCLUSION
Despite classification as a Schedule I controlled sub-
stance for the past twenty-eight years, marijuana is not a
drug with a high potential for abuse, no currently accepted
265. See 21 U.S.C. § 812(b)(3) (1994). A drug is placed on Schedule III if
there is a lower potential for abuse than the drugs in Schedule I and II, there is
a currently accepted medical use, and abuse of the drug may lead to moderate
or low physical dependence or high psychological dependence. See id.
266. See Welcome to 4THC.com (visited May 19, 2000)
<http://www.4thc.com>; Welcome to www.vaporizer.com (visited May 19, 2000)
<httpJ/www.vaporizer.com>.
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medical use, or a lack of safety under medical supervision."'
Although numerous unsuccessful attacks on this status have
taken place in the past, the time has come to recognize the
mounting research supporting the transfer of schedules. The
data objectively indicates that marijuana should be a Sched-
ule III substance. Since the government most likely will not
acquiesce to such a transfer, a transfer to Schedule II appears
more likely. Especially in light of the recent Institute of
Medicine Report, marijuana's time in Schedule I is up.
267. See discussion supra Part IV.
268. See discussion supra Part II.E.
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